Valuation: Glaukos Corporation

Market Cap 10.12B 8.77B 8.29B 7.51B 14.09B 971B 14.19B 98.93B 38.06B 492B 38.02B 37.18B 1,570B P/E 2026 *
-212x
P/E 2027 * 584x
Enterprise Value 9.95B 8.62B 8.15B 7.38B 13.84B 954B 13.95B 97.22B 37.4B 484B 37.36B 36.53B 1,543B EV / Sales 2026 *
14.4x
EV / Sales 2027 * 11.7x
Free-Float
96.37%
Yield 2026 *
-
Yield 2027 * -
1 day+0.34%
1 week-7.22%
Current month-4.39%
1 month-6.96%
3 months+31.92%
6 months+76.95%
Current year+52.05%
1 week 165.43
Extreme 165.43
179.96
1 month 165.43
Extreme 165.43
191.62
Current year 93.96
Extreme 93.96
191.62
1 year 73.16
Extreme 73.16
191.62
3 years 59.22
Extreme 59.22
191.62
5 years 33.33
Extreme 33.33
191.62
10 years 23.08
Extreme 23.075
191.62
Manager TitleAgeSince
Chief Executive Officer 65 31/12/2000
Director of Finance/CFO 56 31/03/2022
President 50 31/03/2022
Director TitleAgeSince
Chairman 65 30/12/2021
Director/Board Member 71 30/06/2014
Director/Board Member 57 30/06/2014
Date Insider Type Main position Quantity % Market Cap. Importance
28/08/26 Sell

Executive/Senior Manager

-13,744 0.0240%
19/08/26 Exercice

Director

7,500 0.0131%
11/08/26 Exercice

Chairperson

180,000 0.3139%
Change 5-day change 1-year change 3-year change Capi.($)
+0.34%-7.22%+112.90%+128.54% 10.12B
-0.13%+1.83%-25.35%-3.85% 108B
-0.82%+0.34%-25.30%-1.86% 11.77B
-0.11%-5.11%-54.48%-71.65% 3.97B
-0.20%-4.44%-28.37%+23.21% 2.36B
+0.38%+20.05%-7.60%-64.63% 2.16B
-0.88%-5.48% - - 1.82B
+0.07%-4.17%-22.83%-30.97% 1.5B
+1.90%-2.18%-37.32%-49.11% 1.41B
Average +0.01%+0.31%-11.04%-8.79% 15.9B
Weighted average by Cap. -0.50%+1.06%-16.13%+2.68%

Financials

2026 *2027 *
Net sales 691M 598M 566M 512M 961M 66.27B 969M 6.75B 2.6B 33.6B 2.6B 2.54B 107B 845M 732M 692M 626M 1.18B 81.02B 1.18B 8.26B 3.18B 41.08B 3.17B 3.1B 131B
Net income -51.88M -44.94M -42.5M -38.47M -72.21M -4.98B -72.75M -507M -195M -2.52B -195M -191M -8.05B 18.93M 16.39M 15.5M 14.03M 26.34M 1.82B 26.54M 185M 71.17M 921M 71.09M 69.52M 2.94B
Net Debt -175M -151M -143M -130M -243M -16.78B -245M -1.71B -658M -8.51B -657M -642M -27.13B -273M -236M -223M -202M -380M -26.17B -383M -2.67B -1.03B -13.27B -1.02B -1B -42.32B
Logo Glaukos Corporation
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others.
Employees
1,094
Date Price Change Volume
15/09/26 US$171.68 +0.34% 621,746
14/09/26 US$171.09 +2.30% 906,311
11/09/26 US$167.25 -1.84% 552,413
10/09/26 US$170.38 -5.23% 1,009,478
09/09/26 US$179.79 -2.84% 587,935
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
171.68USD
Average target price
197.15USD
Spread / Average Target
+14.84%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GKOS Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!